Remsima SC
.png)
Product Description
Celltrion
-comp304625.png)
-
KR -
2022On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Primary activities
Categories
Celltrion
-
KR
-
2022On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Primary activities
More Products from Celltrion (4)
-
Product Remsima
The world's 1st mAb biosimilar • Ingredient: Infliximab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Relieves disease progression by inducing a neutralizing response to tumor necrosis factor(TNF-α), the cause of autoimmune disease • Approval status: 100 countri... -
Product Truxima
• Ingredient: Rituximab • Indication: Non-Hodgkin's lymphoma, rheumatoid arthritis • Mode of mechanism: Specifically binds to CD20, which is expressed on the cell surface of human B cells and lyses target cells to express pharmacological action with mechamisms such as complement-dependent cytotoxicity, ... -
Product Herzuma
• Ingredient: Trastuzumab • Indication: Breast cancer, stomach cancer • Mode of mechanism: Inhibits tumor cell proliferation and growth by binding to a specific antigen (HER2) that occurs specifically and excessively on the surface of tumor cells • Approval status: 80 countries including US, Euro... -
Product Yuflyma
• Ingredient: Adalimumab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Blocks the transmission of inflammatory signals by binding to TNF-α in the body • Approval status: 44 countries including the US(product name: Inflectra), Europe and South Korea
Celltrion resources (3)
-
News Bora Pharmaceuticals partners with Celltrion to crack the APAC market
Bora Pharmaceuticals, the international cGMP CDMO producing specialised pharmaceutical products such as sterile and non-sterile ophthalmics and nasal sprays for clinical use, is partnering with Celltrion Asia Pacific, subsidiary of Celltrion Group Inc. -
News The Korean biopharma market: Incentivizing innovation
With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i].
Frequently Viewed Together
-
Product Custom Protein Synthesis
We provide a Custom Protein Synthesis Service, using a chemical method that synthesises proteins amino acid by amino acid and making modifications on an atomic-scale. We work closely with our partners in designing, customising and optimising the proteins that is synthesized in an automa...
-
Product INJECTABLES
Requiring injectables.EU-GMP is a must.
EU dossier is a must.
Licensing and supply model or distributorship.
-
Product Mipeginterferon alfa-2b
Pegylated human interferon alfa-2b
Trade name: PEGBING
Technology
Recombinant gene technology, expressed by Yeast
Amino acid
165 amino acids
Molecular weight
Approximately 59 kD
Indications
Chronic hepatitis B & C
...
-
Product Sterile Grade at ISO Class 5 facility
Kikkoman can offer "sterile grade” products, purified through a super purification process at our ISO Class 5 facility, approved by the Japanese Authority.
-
Product Protein Aggregation Analysis and Characterization
Analysis and characterization of protein aggregates: The services provided by our experts include a range of protein aggregation analysis techniques that are used to detect and quantify aggregates in solution in support of formulation development, quality control, stability studies, comparability, rel...
-
Product Pipeline
Polpharma Biologics has its own pipeline of biosimilars for out-licensing.
We are focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.
-
Product Heparin-Indar
Prjsc "Indar" provides wide range of antithrombotic products which includes heparin-indar. The product of direct anticoagulant group. Heparin acts fast. Is applied for treatment of thrombembolia and diseases that have risk of thromboembolic complications, for prevention of post surgery venous thrombosis an...
-
Product HANLIKANG (Rituximab Injection)
HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has bee...
-
Product Rasburicase Biosimilar candidate
Paras Biopharmaceuticals has been intensively working on a Romiplostim biosimilar known as Elitek™ / Fasturtec™) and has progressively achieved success. The company plans to mature good value within its Rasburicase asset and would like to highlight the following points / highlights to gauge your level of ...
-
Product Biologics
End-to-end development and manufacturing capabilities across different therapeutic modalities and the entire product lifecycle
Cutting-edge technology platforms for high yielding cell lines (both mammalian and microbial) and high concentration formulations
Integrated and flexible drug sub...
-
Product Gamma Irradiated Cleanroom Facemasks With Tyvek Side Extensions
Gamma Irradiated, Extra Large Cleanroom Facemask with Tyvek® Side Extensions, Green or Blue, with Double Elastic Headbands and with or without Fog-Prevention Adhesive are made from an inner facing of soft cellulose material, an outer facing of spunbonded polypropylene and a 100% meltblown polypropylene med...
-
Product Biotechnology Services
Midas Pharma offers a wide range of pharmaceutical services which include biotechnology services. It offers: • development of biosimilars and proprietary biologicals (starting from gene sequence) • cGMP production (microbial and mammalian cells) • related bioanalytics (from protein biochemical meth...
-
Product Pharmaceutical and Biological Products Contract Development and Manufact...
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO). Our six state-of-the-art cGMP manufacturing facilities across Asia and North America deliver to more than 100 markets around the world. Our sites have the highest industry standards for quality, dev...
-
Product Kemwell Biopharma
SERVICES Kemwell provides integrated development and manufacturing services for companies that require one-stop solution for mammalian cell-culture based protein therapeutics The team is experienced to undertake end-to-end activities right from cell line development till cGMP clinical and commercial manufa...
-
Product Rituximab
Rituximab binds itself to the CD20 protein, marking them, and subsequently triggering the cells of the immune system to pick out the marked cells and kill them.The indication is for Non Hodgkin Lymphoma
-
Product RARE DISEASES & ORPHAN DRUGS
Lodaat has a portfolio pipeline of Rare Disease and Orphan Drug products. USFDA in development, we are looking for partners for the US, GCC, LATAM, EU markets. Many products are made in USA products in FDA approved facilities.
-
Product Biosimilars Portfolio
• Pegfilgrastim (Filed with EMA) • Filgrastim (Filed with EMA) • Trastuzumab (Filed with EMA, MHRA, Received recommendation for marketing authorization in India) • Bevacizumab (Filed with MHRA) • Omalizumab (Global PhIII ongoing) • Denosumab (Global PhIII ongoing) • Ranibizumab (Global PhIII ongoing...
-
Product Eylea biosimilar vial & PFS
1.Completion of global clinical trials phase Ⅲ
2. Completion of pre-submission meetings with advanced regulatory authorities
3. Available in Vial and PFS
-
Product Biologic drug substance CDMO services
From pre-clinical development to commercial supply, Patheon by Thermo Fisher Scientific is an industry leader in the development and manufacture of mammalian cell culture drug substances. Patheon offers biotech and pharmaceutical companies the ability to pursue opportunities around the globe with a fully i...
-
Product Leuprolide 3-Month Implant
The active ingredient leuprorelin, like goserelin, is a synthetic peptide that can be used primarily in the treatment of hormone-dependent tumors, particularly prostate cancer. Administration of leuprorelin has indirect effects on testosterone levels in men, the lowering of which stops the growth of malign...
-
Product Biosimilars
Portfolio of high-producing biosimilar cell lines and processes, off-the-shelf and generation of such from scratch. Biosimilarity optimisation of your recombinant cell line. Your benefit: Cost and time-savings, while bringing your product to the market. https://excellgene.com/offerings/biosimilars/
-
Product Method Development
We are specialist in the method development of analytical methods for analysis of API, Final Drug Products or low level impurities. Usually followed by full validation in accordance to ICH guidelines.
-
Product Interview by Newsweek, time to talk
Interviewee：Dr. Steve J.P. Hsu (President of Genovior Biotech)
-
Product Technology Transfer-Biosimilars
"If you're interested in Tech Transfer projects, our team is well-prepared to assist you with Biosimilar products such as Insulin or Monoclonal Antibodies. We have a network of over 10,000 partners who are willing to explore these opportunities. Please don't hesitate to reach out for more information on th...-comp316899.png)
-
Product Biomedtracker
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the marke...
-
Product Recombinant human granulocyte colony-stimulating factor injection (filgr...
Shandong kexing bioproducts offers a wide range of products which includes recombinant human granulocyte colony-stimulating factor injection (filgrastim). It is colorless sterile solution. Packaging: vial. Storage: store at 2?~8?, and protect from light. Contact us for more information.
-
Product Monomaterial Packaging Specialist
Pharma and Biotech toploading and sideloading cartoning systems from the monomaterial specialistDividella from Switzerland provides pharma and biotech packaging systems for the secondary packaging of parenterals. Dividella's patented top-loading and recently also side-loading cartoners package syringes, vi...
-
Product Ficocyte
Filgrastim 30 MU /0.5 ml It is a synthetic version of a certain natural substance made in human body. It helps the bone marrow to produce new white blood cells. Filgrastim is given to people whose ability to produce white blood cells is reduced, due to chemotherapy, chronic neutropenia, or exp...
-
Product Walk in Cooling Cabinet.
The Walk-In Cooling Cabinets / cold rooms are designed according to ICH guidelines, WHO, MCA and USFDA requirements to maintain uniform conditions. They are superior in airflow distribution, temperature control technology, cabinet construction and are manufactured as per cGMP regulations.
Biggest Walk...
-
Product EPOMAX 2000 (RECOMBINANT HUMAN ERYTHROPOEITIN ALPHA? 2000 UI / 1 ml)
After granting the Marketing Authorization of THE FIRST Human Recombinant alpha Erythropoietin (EPO), MédiS becomes the FIRST Tunisian pharmaceutical company to produce and market its biosimilar EPO commercially appointed as EPOMAX®.
-
Product RinLis® Mix 25
Insulin lispro biphasic 25.Dosage form: susupension for subcutaneous injections in 3 ml cartridges and pre-filled disposable insulin pen.
· Has fast and predictable effect and the elimination typical for physiologic insulin secretion.
·...
-
Product Biopharmaceutical Characterisation and Testing Services
Characterization and testing of biopharmaceuticals: Using our expert's insight into a biologic's structure, physicochemical properties, potency, and impurity profile, we help you meet your development milestones.
A range of expertise is available, including assessment of structure...
-
Product Ready-to Use CHO cell lines
UGA Biopharma GmbH offers to their clients so called Ready-to-use Biosimilar Cell Lines. This are in-house developed CHO cell lines stably expressing different biosimilar molecules, that are instantly available for in-licensing. The client profits, because the cell lines are directly available, and develop...
-
Product Yuflyma
• Ingredient: Adalimumab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Blocks the transmission of inflammatory signals by binding to TNF-α in the body • Approval status: 44 countries including the US(product name: Inflectra), Europe and South Korea
-
Product UV Light Blocking Tyvek Equipment Covers
UV Light Blocking Tyvek Equipment Covers are designed to keep cleaned pharmaceutical equipment and supplies clean and protected from external sources of contamination while also providing in-process protection to light sensitive biotech products.
-
Product Biomarker Assays and Validation
Validation of biomarker assays: Our diverse range of analytical platforms supports biomarker analyses including ELISA, flow cytometry, cell-based assays, multiplex ECL platforms, and high sensitivity measurements using QuanterixSimoa HD-X Analyzer™ measurement instruments. Our dedicated biomarker assay...
-
Product HANBEITAI (Bevacizumab Injection)
HANBEITAI (generic name: bevacizumab), the fourth product independently developed by Henlius, received marketing approval from the National Medical Products Administration (NMPA) in November 2021, and its commercialization in Chinese mainland is handled by the company’s in-house team. As of now, HANBEI...
-
Product Biosimilars, and High Value Molecules
Lodaat has an extensive portfolio of Biosimilars, Biologics, and High Value Molecules including ADCs, MABs and other large molecules. We are looking for reputable global partners who want to expand their product line and in-license for their territory.
-
Product Anakinra Biosimilar Candidate
Paras Biopharmaceuticals has been intensively working on a Anakinra / IL1-RA biosimilar known as Kineret™) and has progressively achieved success. The company plans to mature good value within its Anakrina / IL1-RA asset and would like to highlight the following points / highlights to gauge your level of ...
-
Product Basalin®(insulin glargine injection)
Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24...
-
Product Romiplostim Biosimilar Candidate
Due to the complex nature of the product, Paras Biopharmaceuticals has been intensively working on this complex drug (Nplate™) for over 6 years and has progressively achieved success. The company plans to mature good value within its Romiplostim asset (Biosimilar) and would like to highlight the following...
-
Product Biosimilars Testing Services
Testing services for biosimilars: Our biosimilar analytical comparability programs provide highly relevant data for early stage characterisation and later stage comparison. These programs evaluate and compare all pertinent features of the biosimilar product and are based on the ICH Q6B. Programs encompa...
-
Product Post-translational modifications
Intertek offers wide range of pharmaceutical services which includes post-translational modifications. It belongs to biopharmaceutical protein analysis services category. It includes deamidation, glycosylation, glycylation, phosphorylation, acetylation , alkylation, sulfation, etc.
-
Product Humodar C25 100R
PRJSC 'Indar' provides wide range of insulin products in vials and cartridges which includes humodar c25 100r. Its an anti-diabetic product of short effect. Ensures quick decrease of glucose level in the blood, intensifies its absorption by tissues. The effect starts after 30 minutes and can last within 5-...
-
Product Protamine sulfate
Prjsc "Indar" provides wide range of antidotes products which includes protamine sulfate. The product is an efficient antidote to heparin of equivalent dosage: 1 mg of protamine sulfate neutralizes 1 mg of heparin. The effect occurs instantly (“on the needle”) and lasts for approximately 2 hours. Is usuall...
-
Product Protein Therapeutic Glycosylation Studies
In line with ICH Q6B, we deliver glycosylation analysis for proteins, antibodies, bispecifics including assessment of the glycosylation site, carbohydrate content and glycan structure. With a range of MS approaches, our protein characterisation scientists provide detailed glycosylation studies designed to ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance